Pfizer cuts Alzheimer’s and Parkinson’s research: industry news round-up

Written by Roisin Conneely

From clinical trial results to major policy change announcements, here we present an overview of the latest industry news from the biggest players in neuroscience and neurology. Our pick of the biggest headlines this week: Pfizer to end research into novel drugs for Alzheimer’s and Parkinson’s diseases Shire to begin operating as two units, focusing on neuroscience and rare disease Phase III clinical trial results for idalopirdine in the treatment of Alzheimer’s disease Pfizer to end research into novel drugs for Alzheimer’s and Parkinson’s diseases The week began with the news that Pfizer Inc. (NY, USA) is planning to cease...

To view the full article, please register now for access

It's completely free